Secondary Zika virus infection do not support evidences of Antibody-Dependent Enhancement in vivo in dengue pre-exposed rhesus macaques

Similar documents
Immunopathogenesis of Dengue Hemorrhagic Fever

Centers for Disease Control and Prevention Zika Diagnosis: Challenges and Opportunities

Zika Virus Infection in Cynomolgus Macaques

Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees

Zika virus: laboratory diagnosis

: AccuPower ZIKV(DENV, CHIKV) Multiplex Real-Time RT-PCR Kit. Copyright, Bioneer Corporation. All rights reserved.

Development of a Recombinant Subunit Dengue Vaccine. Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller

Supplementary Table 1: Summary of Reactogenicity Events by Group and Time of Onset in Entebbe

111 II1 I 111 III ? 0 9, AD-A CT 31i931 ANNUAL REPORT D TIC RDMUNDO KRAISELBURD S AUGUST 28, 1991.

Immunology. Overview. Kris.ne Kra1s, M.D.

What is the role of animal models in studying protective titres and the need for establishing surrogates/correlates of protection?

Dengue: The next vaccine preventable disease? Prof John McBride James Cook University

Update on the NIH tetravalent dengue vaccine. Beulah Sabundayo, PharmD, MPH Johns Hopkins Bloomberg School of Public Health

Arbovirus Epidemiology and Diagnosis Educational Session Curacao 2016 R. Steingrover Clinical Microbiologist ADC

Marmoset-based infectious disease research under biocontainment conditions

Human B Cell Responses to Influenza Virus Vaccination

Building Zika preparedness in the Region of the Americas: research response

A Recombinant Tetravalent Dengue Vaccine Candidate Using DENV-2 Backbone

Nature Medicine: doi: /nm.4322

NON HUMAN PRIMATE BIOMEDICAL RESEARCH FOR TACKLING EMERGING INFECTIOUS DISEASES (II): ZIKA VIRUS. Special series on Laboratory Animal Science

Objectives. Dengue, Chikungunya and Zika Virus Infection: Answers to Common Questions. Case 1. Dengue Introduction 10/15/2018

Outbreaks of Zika Virus: What Do We Know? Presented by Dr Jonathan Darbro Mosquito Control Lab, QIMR Berhgofer 15 September 2016

COUNTERING EMERGING INFECTIOUS DISEASE THREATS

The Interplay between Zika and other flaviviruses: overview and results from Brazil

MODULE 5. Dengue. Edwin J. Asturias Associate Professor of Pediatrics Senior Investigator Director for Latin America

Overview of role of immunologic markers in HIV diagnosis

Adaptive Immunity. Lecture 14 Biology W3310/4310 Virology Spring Life is simple, but we insist on making it complicated CONFUCIUS

Increased IL-10 levels during dengue virus infection. Dr. Ana B. Perez Dept. Virology Institute for Tropical Medicine Pedro Kouri Cuba

Section D. Identification of serotype-specific amino acid positions in DENV NS1. Objective

1. Dengue An Overview. Dengue Expert Advisory Group

Summer!2016! Undergraduate! Research! Internships!

Joseph E. Blaney, Jr.,* Jennifer M. Matro, Brian R. Murphy, and Stephen S. Whitehead

Zika Virus Basics. Flaviviridae Flavivirus Disease Vector Vaccine *Dengue (serotypes 1-4) Zika Virus Basics. Zika Virus Transmission Cycle

DENGUE AND BLOOD SAFETY. Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo

Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells

ZIKA VIRUS SHIPPING SOLUTIONS

4. Th1-related gene expression in infected versus mock-infected controls from Fig. 2 with gene annotation.

HIV Basics: Clinical Tests and Guidelines

Results of Phase III Efficacy Studies in Dengue Endemic Regions of the Sanofi Pasteur Candidate Dengue Vaccine

ANTIBODIES DETERMINE VIRULENCE IN DENGUE. Scott B HALSTEAD, M.D. DIRECTOR, Research Pediatric Dengue Vaccine Initiative IVI, Seoul, Korea

DIAGNOSTICS ALGORITHMS IN DENGUE INFECTIONS

Correlates of Protection in Dengue. Stephen J. Thomas, MD Division of Infectious Diseases State University of New York Upstate Medical University

Supporting Information

IMMUNE RESPONSE TO INFECTIOUS DISEASES

Dengue NS1 Antigen - for Early Detection of Dengue Virus Infection

Update on influenza vaccination using microneedle delivery

Replicating measles-shiv vaccine induces long term preservation of central memory CD4 cells in the gut of macaques challenged with SHIV89.

A. Study Purpose and Rationale

EVALUATION OF LH 750 VCS PARAMETERS AND LYMPH INDEX IN IDENTIFYING DENGUE FEVER

Updates in Infectious Diseases. Kelley Struble, DO, MS St. John Physicians Infectious Disease September 30, 2016

ZIKA VIRUS AND SAFETY OF THE BLOOD SUPPLY. Michael P Busch, MD, PhD Blood Systems Research Institute University of California, San Francisco

Dengue Vaccine Butantan Institute. DCVMN, Bangkok, 2015

Everything you ever wanted to know about Zika Virus Disease

From Mosquitos to Humans: Genetic evolution of Zika Virus

SUPPLEMENTARY INFORMATION

Dengue and Zika vaccine development

Physiology Unit 3 THE SPECIFIC IMMUNE RESPONSE

Zika Virus Update March 21, 2018

Prevention of transfusion-transmitted arboviruses in French Polynesia

Figure S1. Alignment of predicted amino acid sequences of KIR3DH alleles identified in 8

Dengue Fever & Dengue Hemorrhagic Fever Annual Reports to WHO

Geneva, March Consultation background

Emergence du Chikungunya dans les Antilles et caractéristiques virologiques de l épidémie

Supporting Information

Role of a ZIKV CHIM in vaccine evaluation. Anna Durbin Johns Hopkins Bloomberg School of Public Health WHO Zika Workshop, Geneva 2 June 2017

Dynamics of lentiviral infection in vivo in the absence of adaptive immune responses

Supplementary Appendix

Received 4 December 2001/Accepted 29 April 2002

Memory NK cells during mousepox infection. Min Fang, Ph.D, Professor Institute of Microbiology, Chinese Academy of Science

Immunity. Skin. Mucin-containing mucous membranes. Desmosome (attaches keratincontaining. Fig. 43.2

There are 2 major lines of defense: Non-specific (Innate Immunity) and. Specific. (Adaptive Immunity) Photo of macrophage cell

Skin. Mucin-containing mucous membranes. Desmosome (attaches keratincontaining

NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections

Flavivirus Vaccines Japanese Encephalitis and Dengue

HYPERIMMUNOGLOBULIN and CMV- DNAemia IN PREGNANT WOMEN WITH PRIMARY CYTOMEGALOVIRUS INFECTION

HIV Basics: Pathogenesis

Correlates of Vaccine-induced Immunity

Immune protection against dengue infection. Vaccine performance

JAK3 inhibitor administration in vivo in chronically SIV Infected Rhesus Macaques

Supplementary Information for. Diagnosis of Zika virus infection on a nanotechnology platform

Retrospective serological study on sequential dengue virus serotypes 1 to 4 epidemics in Tainan City, Taiwan, 1994 to 2000

Supplementary information. Early development of broad neutralizing antibodies in HIV-1 infected infants

Received 29 August 2002/Accepted 3 December 2002

What s Lurking out there??????

Evaluation of platforms to detect Zika and West Nile virus from honeycards

Dengue pathogenesis and vaccine design

Impact of irradiation and immunosuppressive agents on immune system homeostasis in rhesus macaques

La risposta immune all infezione da virus ebola. Chiara Agrati, PhD

Supporting Information

Overview of Zika. Alan D.T. Barrett Department of Pathology Sealy Center for Vaccine Development University of Texas Medical Branch Galveston TX

Dengue Symptoms Significance in Anti-Dengue Drug Development: Road Less Travelled

Chapter. Severe Acute Respiratory Syndrome (SARS) Outbreak in a University Hospital in Hong Kong. Epidemiology-University Hospital Experience

New epidemiological perspectives coming from dengue vaccine clinical trials. João Bosco Siqueira Jr Federal University of Goias - Brazil

ZIKA VIRUS. Epic and aspects of management

B and T cell Memory. Bengt Lindbom Adap6ve Immunity BMC D14

Acute lung injury in children : from viral infection and mechanical ventilation to inflammation and apoptosis Bern, R.A.

Table S1. Viral load and CD4 count of HIV-infected patient population

Test Definition: FMCPS Meningoencephalitis Comprehensive Panel (Serum)

Categorisation of Dengue based on duration of fever and serological markers in a tertiary care hospital

Severe acute respiratory syndrome-coronavirus infection in aged nonhuman primates is associated with modulated pulmonary and systemic immune responses

Transcription:

University of Puerto Rico Medical Sciences Campus Caribbean Primate Research Center Secondary Zika virus infection do not support evidences of Antibody-Dependent Enhancement in vivo in dengue pre-exposed rhesus macaques Zika virus WORK IN PROGRESS AT Caribbean Primate Research Center Version 1.1, September 5, 216

Experimental Overview Cohort 1 DENV infected 5x1^5 pfu by s.c. DENV-1 WP74 DENV-2 NG44 ZIKV Infection FP/H/213 1 x 1^6 pfu by s.c October 213 Bled August 1 st 216 N=4 DENV-1 WP74 DENV-2 NG44 Rhesus Macaques Time after DENV Infection: Months 12 18 3 ZIKV: Month 34 Cohort 2 DENV-Naive N=4

Cross reactivity in ELISA to DENV and ZIKV before ZIKV infection* O.D 1.4 1.2 1..8.6 Total IgG anti-denv an- Abs O.D..8.7.6.5.4.3 Total IgG anti an- ZIKV ZIKV NS1 NS1 Abs.4.2.2. Baseline 3 D 6 D 1 Y 2.5 Y.1. Baseline 3 D 6 D 1 Y 2.5 Y Time after dengue infection Time after dengue infection DENV1 and DENV2 exposed animals. *Samples collected up to 1 year a6er DENV infec<on, were collected in year 214, before ZIKV was introduced in LA region.

Observations ELISA results include four animals per DENV group (DENV1 and 2). However only two per group were ZIKV- infected. All exposed animals showed an increase of DENV an<body <ters a6er DENV infec<on. Only animals exposed to DENV2 showed cross- reac<vity to ZIKV- NS1 a6er 3 days of DENV infec<on. Cross- reac<vity persist in most of the animals up to 2.5 years later.

Pre-existing immunity to DENV before ZIKV infection Dengue IgG ZIKV IgG NS1 DENV-Neut titer ZIKV-Neut titer ID (infecting serotype) SAMPLE DATE TIME POINT RESULT RESULT 5/6/8% 5/6/8% RM1 (D1) 9/24/13 BASELINE NEG NEG D1 <2/<2/<2 <2/<2/<2 RM2 (D1) 8/1/13 BASELINE NEG NEG D1 <2/<2/<2 <2/<2/<2 RM3 (D2) 8/14/13 BASELINE NEG NEG D2 <2/<2/<2 <2/<2/<2 RM4 (D2) 8/14/13 BASELINE NEG NEG D2 <2/<2/<2 <2/<2/<2 RM1 (D1) 11/4/13 DAY 3 POS NEG 32/32/32 <2/<2/<2 RM2 (D1) 11/4/13 DAY 3 POS NEG 64/64/32 <2/<2/<2 RM3 (D2) 11/2/13 DAY 3 POS POS 128/128/128 <2/<2/<2 RM4 (D2) 11/2/13 DAY 3 POS POS 128/128/128 <2/<2/<2 RM1 (D1) 12/3/13 DAY 6 POS NEG D1 in Progress In Progress RM2 (D1) 12/3/13 DAY 6 POS NEG D1 in Progress In Progress RM3 (D2) 12/17/13 DAY 6 POS POS D2 in Progress In Progress RM4 (D2) 12/17/13 DAY 6 POS POS D2 in Progress In Progress RM1 (D1) 1/22/14 1 YEAR POS NEG 128/128/64 <2/<2/<2 RM2 (D1) 1/22/14 1 YEAR POS NEG 32/16/16 <2/<2/<2 RM3 (D2) 1/22/14 1 YEAR POS POS 128/128/128 <2/<2/<2 RM4 (D2) 1/22/14 1 YEAR POS NEG 128/128/64 <2/<2/<2 RM1 (D1) 4/1/16 2.5 YEAR POS NEG 16/16/8 <2/<2/<2 RM2 (D1) 4/1/16 2.5 YEAR POS NEG 128/64/64 <2/<2/<2 RM3 (D2) 4/1/16 2.5 YEAR POS POS 128/128/64 <2/<2/<2 RM4 (D2) 4/1/16 2.5 YEAR POS NEG 32/32/16 <2/<2/<2 RM5 (Naïve) 7/5/16 BASE L Before ZIKA NEG NEG <2/<2/<2 <2/<2/<2 RM6 (Naïve) 7/5/16 BASE L Before ZIKA NEG NEG <2/<2/<2 <2/<2/<2 RM7 (Naïve) 7/5/16 BASE L Before ZIKA NEG NEG <2/<2/<2 <2/<2/<2 RM8 (Naïve) 7/5/16 BASE L Before ZIKA NEG NEG <2/<2/<2 <2/<2/<2 *Challenged on August 1st, 216

Observations Acute or convalescent samples a6er DENV infec<on do not neutralize ZIKV in vitro.

Serum Viremia Viremia genome copy/ml 1 9 1 8 1 7 1 6 1 5 1 4 1 3 1 2 1 1 1 1 2 3 4 5 6 7 8 9 1 15 Days after ZIKV infection Naive DENV-immune DENV1 and DENV2 pre- exposed animals.

Observations ZIKV peak viremia is not modified by pre- exis<ng immunity to DENV. In general, animals pre- exposed to DENV showed shorter ZIKV viremia compared to DENV- naïve animals.

Serum Viremia vs. Neut Antibodies Group Uninfected controls Monkey ID Viremia a (log 1 genome equivalent/ml) during days 1-1 post Zika infection Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 1 Day 15 Average Duration (days) Pre challenge anti-denv1 Neut 5 Pre challenge anti-denv2 Neut 5 Pre challenge anti-zikv Neut 5 RM5 + + + + + - - - - - + <2 <2 <2 3 days Post challenge anti- DENV1 Neut 5 3 days Post challenge anti- DENV2 Neut 5 3 days Post challenge anti-zikv Neut 5 P P P RM6 + + + + + - - - - - + <2 <2 <2 P P P RM7 + + + + + + + - - + - 6.5 <2 <2 <2 P P P DENV1 Infected DENV2 infected P: In progress RM8 + + + + - - - + - - <2 <2 <2 P P P RM1 + + + + - - - - - - 16 ND <2 P P P RM2 + + + + - + + 128 <2 - - - - 5.5 ND P P P RM3 + + + + + + - - - - + ND 128 <2 P P P RM4 + + + + - + - - - - - ND 32 <2 P P P

Observations In animals pre- exposed to DENV, neutraliza<on <ters do not correlates with the peak or the magnitude of viremia a6er infec<on with ZIKV.

Laboratory Parameters After ZIKV infection 15 WBC 8 Lymphocytes 1 Neutrophils WBC x 1^3/ul 1 5 Values in % 6 4 2 Values in % 8 6 4 2 7 15 Days after ZIKV infection 7 15 Days after ZIKV infection 7 15 Days after ZIKV infection Monocytes ALT AST 15 15 15 Values in % 1 5 ALT U/L 1 5 AST U/L 1 5 7 15 Days after ZIKV infection 7 15 Days after ZIKV infection 7 15 Days after ZIKV infection DENV2 and DENV1- exposed animals; Naïve animals.

Observations Similar to other viral infec<ons, there was an ini<al decrease in the total WBC count at 7 days a6er infec<on in both cohorts of animals and returning to baseline levels by day 15. There is a slight increase in the % of lymphocytes that decrease at 7 days a6er infec<on both in naïve and pre exposed animals. There was an clear ini<al increase in the % of monocytes at 7 days a6er infec<on, more evident in cohort 1. This increase tends to be higher in the animals exposed to DENV2 compared to those exposed to DENV1. Both ALT and AST, but par<cularly ALT showed a strong trend (p =.9) to be higher in naïve animals exposed to ZIKV than in animals with previous immunity to any of the two dengue serotypes. These results suggest a protec-ve role to the liver damage by the DENV pre- exis-ng immunity.

Observations Generalized Rash in RM1 (DENV1 pre- exposed macaque) seen by day 8 a6er infec<on. Rash was s<ll present a6er 23 days of infec<on. We are evalua<ng the rash evolu<on and the meaning in the context of ZIKV infec<on and dengue- pre exis<ng immunity. Other causes of rash are being ruling out.

CD69+ B cells CD69+ NK16 cell Relative Change (% of baseline) 2 15 1 5 Baseline 24 H 48 H 7 Days 1 Days Time after ZIKV infection 15 Days Naive DENV-immune Relative Change (% of baseline) 1 8 6 4 2 Baseline 24 H 48 H 7 Days 1 Days Time after ZIKV infection 15 Days Naive DENV-immune CD69+ T4 cells CD69+ T8 cells Relative Change (% of baseline) 25 2 15 1 5 Baseline 24 H 48 H 7 Days 1 Days 15 Days Naive DENV-immune Relative Change (% of baseline) 4 3 2 1 Baseline 24 H 48 H 7 Days 1 Days 15 Days Naive DENV-immune Time after ZIKV infection Time after ZIKV infection Flow Cytometry Results. Red and blue squares: DENV2 and DENV1 pre- infected animals.

Observations The frequency of B cells ac<va<on was significant at 24 and 48 hours a6er infec<on compared to the basal level in both cohorts. The frequency of ac<vated B cells was sta<s<cally higher in the naïve group at 48 hours and 1 days a6er the infec<on compared to the DENV pre- exposed animals. In both cohorts ac<vated NK16 cells increased at 48 hours a6er the infec<on, with a decrease in the frequency of ac<va<on by day 7, returning to baseline levels by day 15. However, differences in the frequency of ac<va<on was not significant in any cohort. CD4+ T cells ac<va<on was significantly higher in both cohorts at 24, 48 hours and by day 1. However the frequency and magnitude of CD4+/CD69+ cells showed a trend to be higher in the naïve animals. There is a significant increase in the frequency of CD8+/CD69+ cells at 24 and 48 hours a6er infec<on in both cohorts. However the magnitude of ac<va<on trend to be higher in naïve animals.

Upcoming Results ZIKV in Saliva: In Progress ZIKV in urine: In Progress Serum Cytokines Quality and magnitude of ZIKV and DENV Neutralizing An<bodies several <mes a6er ZIKV infec<on More Clinical data: Weight, Temperature More immunological data: DC, MO, NK8 cells In vitro ADE using samples before and a6er ZIKV infec<on Characteriza<on of the epitopes linked to ZIKV vs. DENV neutraliza<on Dengue infec<on of ZIKV- exposed animals

This work is being performed by Caribbean Primate Research Center Virology Laboratory Medical Sciences Campus University of Puerto Rico Petraleigh Pantoja, MT, MSc, PhDc Erick X. Pérez- Guzmán, PhDst Crisanta Serrano, PhDst Teresa Arana, MT, MSc Lorna Cruz, MT Ian Cacho, Undergrad. Student Juan F. Or<z, Undergrad. Student Carlos A. Sariol, MD and PI Animal Resources Center, Medical Sciences Campus University of Puerto Rico Idia V. Rodríguez, DVM Yazmin B. Massa Muñoz, LAHT, HIA Animal Health Technologist II Frances Venegas Marvnez, AHT Animal Health Technologist II Lucila López Laboy, AHT, RILAM Animal Health Technologist III José A. Vientos Valle, DVM Melween I. Marvnez, DVM Flow Cytometric Analysis was conducted in collabora<on with SWNPRC at Department of Virology Immunology: Luis Giavedoni, PhD & Vida Hodara, PhD

Citing this work: Petraleigh Pantoja, Erick X. Pérez-Guzmán, Crisanta Serrano, Idia V. Rodríguez, Teresa Arana, Lorna Cruz, Melween I. Martínez, Vida Hodara, Luis Giavedoni, Carlos A. Sariol*. Secondary Zika virus infection do not support evidences of Antibody-Dependent Enhancement in vivo in dengue pre-exposed rhesus macaques. 216. p. 1-16. http://nprcresearch.org/primate/hot-topics/cprc-zika-virus-research-page.pdf This work is par<ally supported by Grants 2 P4 OD12217 to MIM and CAS and 2U42OD21458-15 to MIM and CAS